Adaptive Biotechnologies Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Chad Robins
- Full Time Employees
- 624
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1165 Eastlake Avenue East Seattle WA United States of America 98109
- IPO Date
- Jun 27, 2019
- CIK
- 0001478320
- Website
- adaptivebiotech.com
- Similar Companies
- Business
- Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation (ADPT) develops an immune medicine platform that harnesses the adaptive immune system to create clinical diagnostics, research tools, and therapeutic insights through high-throughput sequencing of T-cell receptors (TCRs) and B-cell receptors (BCRs); its core products and services include clonoSEQ, an FDA-cleared minimal residual disease (MRD) test for monitoring blood cancers such as multiple myeloma, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL); immunoSEQ, a research-use-only platform for immune repertoire profiling used by academic, pharmaceutical, and biotech researchers in biomarker discovery and therapeutic development; T-Detect, a T-cell-based diagnostic platform targeting diseases like Lyme disease, Crohn's disease, multiple sclerosis, and infectious conditions; and immune medicine solutions encompassing pharma services and drug discovery partnerships. Founded in 2009 by brothers Chad Robins and Harlan Robins along with Christopher Carlson, and headquartered in Seattle, Washington, with additional facilities in South San Francisco, California, the company operates primarily in the United States, serving clinical, research, and biopharmaceutical customers focused on oncology, autoimmune disorders, and infectious diseases. Recent developments include the August 2025 termination of its multi-year collaboration with Genentech, a Roche subsidiary, which ended exclusivity obligations in oncology cell therapies and enabled recognition of approximately $41.2 million in non-cash revenue across 2025 while allowing Adaptive Biotechnologies to pivot toward digital TCR-antigen prediction models, new partnering opportunities, and a T-cell depletion program in autoimmunity; ongoing expansion of clonoSEQ adoption with projected 35% growth in fiscal 2025 test volumes; and strategic emphasis on profitability through controlled operating expenses amid $170 million in 2023 revenues and $158 million for the first nine months of 2024.
Company News
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $304,272.41 in Stock
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
Adaptive Biotechnologies Corp (ADPT) Stock Down 3.5% but Still Overvalued -- GF Score: 68/100
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Rated “Moderate Buy” by Sell-Side Brokerages
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High – Still a Buy?
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
Financial Comparison: Charles River Laboratories International (NYSE:CRL) versus Adaptive Biotechnologies (NASDAQ:ADPT)
Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year High – Should You Buy?
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Algert Global LLC Has $2.83 Million Position in Adaptive Biotechnologies Corporation $ADPT
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science
Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT
Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder
Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?
Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript
Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
Adaptive Biotechnologies Q2 Earnings Call Highlights